Synthesis and characterization of an anti-apoptotic immunosuppressive compound for improving the outcome of islet transplantation

Hao Wu, Jayaprakash Pagadala, Charles Ryan Yates, Duaned Miller, Ram I. Mahato

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

Mycophenolic acid (MPA) is a commonly used immunosuppressive drug for human islet transplantation. However, it is toxic to transplanted islets, causing primary nonfunction. We recently synthesized a quinic acid derivative, 1,3,4,5-tetrahydroxy-N-propylcyclohexanecarboxamide (KZ41), which has anti-inflammatory and anti-apoptotic effects. We hypothesized that the conjugate (E)-2,3,5-trihydroxy-5-(propylcarbamoyl) cyclohexyl 6-(4-ethoxy-6-methoxy-7- methyl-3-oxo-1,3-dihydroisobenzofuran-5-yl)-4-methylhex-4-enoate (JP-3-110), which is composed of KZ41 and MPA through esterification, can suppress the immune rejection while inducing less toxicity. Early characterization showed that the solubility of JP-3-110 was significantly higher than that of MPA, though JP-3-110 was still poorly water-soluble. The ester bond connecting KZ41 and MPA is stable for a limited duration (<4 weeks). Pharmacological studies demonstrated that JP-3-110 induced significantly less activated caspase 3 and apoptotic cell death of human islets than MPA, while maintaining an equally potent immunosuppressive effect. A similar immunosuppressive effect of JP-3-110 and MPA in humanized NOD.Cg-PrkdcscidIl2rgtm1Wjl/SzJ (NOD scid gamma, NSG) mice with adoptively transferred human immunity was observed. Taken together, our results demonstrated that JP-3-110 can be a safer immunosuppressive agent for human islet transplantation.

Original languageEnglish (US)
Pages (from-to)2036-2044
Number of pages9
JournalBioconjugate Chemistry
Volume24
Issue number12
DOIs
StatePublished - Dec 18 2013

Fingerprint

Islets of Langerhans Transplantation
Mycophenolic Acid
Immunosuppressive Agents
Acids
Quinic Acid
Esterification
Poisons
Cell death
2,3,5-trihydroxy-5-(propylcarbamoyl)cyclohexyl 6-(4-ethoxy-6-methoxy-7-methyl-3-oxo-1,3-dihydroisobenzofuran-5-yl)-4-methylhex-4-enoate
Caspase 3
Solubility
Toxicity
Immunity
Esters
Cell Death
Anti-Inflammatory Agents
Pharmacology
Derivatives
Water
Pharmaceutical Preparations

ASJC Scopus subject areas

  • Biotechnology
  • Bioengineering
  • Biomedical Engineering
  • Pharmacology
  • Pharmaceutical Science
  • Organic Chemistry

Cite this

Synthesis and characterization of an anti-apoptotic immunosuppressive compound for improving the outcome of islet transplantation. / Wu, Hao; Pagadala, Jayaprakash; Yates, Charles Ryan; Miller, Duaned; Mahato, Ram I.

In: Bioconjugate Chemistry, Vol. 24, No. 12, 18.12.2013, p. 2036-2044.

Research output: Contribution to journalArticle

Wu, Hao ; Pagadala, Jayaprakash ; Yates, Charles Ryan ; Miller, Duaned ; Mahato, Ram I. / Synthesis and characterization of an anti-apoptotic immunosuppressive compound for improving the outcome of islet transplantation. In: Bioconjugate Chemistry. 2013 ; Vol. 24, No. 12. pp. 2036-2044.
@article{eab6e29cdfba4d4bbc9635b88ebd26ab,
title = "Synthesis and characterization of an anti-apoptotic immunosuppressive compound for improving the outcome of islet transplantation",
abstract = "Mycophenolic acid (MPA) is a commonly used immunosuppressive drug for human islet transplantation. However, it is toxic to transplanted islets, causing primary nonfunction. We recently synthesized a quinic acid derivative, 1,3,4,5-tetrahydroxy-N-propylcyclohexanecarboxamide (KZ41), which has anti-inflammatory and anti-apoptotic effects. We hypothesized that the conjugate (E)-2,3,5-trihydroxy-5-(propylcarbamoyl) cyclohexyl 6-(4-ethoxy-6-methoxy-7- methyl-3-oxo-1,3-dihydroisobenzofuran-5-yl)-4-methylhex-4-enoate (JP-3-110), which is composed of KZ41 and MPA through esterification, can suppress the immune rejection while inducing less toxicity. Early characterization showed that the solubility of JP-3-110 was significantly higher than that of MPA, though JP-3-110 was still poorly water-soluble. The ester bond connecting KZ41 and MPA is stable for a limited duration (<4 weeks). Pharmacological studies demonstrated that JP-3-110 induced significantly less activated caspase 3 and apoptotic cell death of human islets than MPA, while maintaining an equally potent immunosuppressive effect. A similar immunosuppressive effect of JP-3-110 and MPA in humanized NOD.Cg-PrkdcscidIl2rgtm1Wjl/SzJ (NOD scid gamma, NSG) mice with adoptively transferred human immunity was observed. Taken together, our results demonstrated that JP-3-110 can be a safer immunosuppressive agent for human islet transplantation.",
author = "Hao Wu and Jayaprakash Pagadala and Yates, {Charles Ryan} and Duaned Miller and Mahato, {Ram I.}",
year = "2013",
month = "12",
day = "18",
doi = "10.1021/bc400369t",
language = "English (US)",
volume = "24",
pages = "2036--2044",
journal = "Bioconjugate Chemistry",
issn = "1043-1802",
publisher = "American Chemical Society",
number = "12",

}

TY - JOUR

T1 - Synthesis and characterization of an anti-apoptotic immunosuppressive compound for improving the outcome of islet transplantation

AU - Wu, Hao

AU - Pagadala, Jayaprakash

AU - Yates, Charles Ryan

AU - Miller, Duaned

AU - Mahato, Ram I.

PY - 2013/12/18

Y1 - 2013/12/18

N2 - Mycophenolic acid (MPA) is a commonly used immunosuppressive drug for human islet transplantation. However, it is toxic to transplanted islets, causing primary nonfunction. We recently synthesized a quinic acid derivative, 1,3,4,5-tetrahydroxy-N-propylcyclohexanecarboxamide (KZ41), which has anti-inflammatory and anti-apoptotic effects. We hypothesized that the conjugate (E)-2,3,5-trihydroxy-5-(propylcarbamoyl) cyclohexyl 6-(4-ethoxy-6-methoxy-7- methyl-3-oxo-1,3-dihydroisobenzofuran-5-yl)-4-methylhex-4-enoate (JP-3-110), which is composed of KZ41 and MPA through esterification, can suppress the immune rejection while inducing less toxicity. Early characterization showed that the solubility of JP-3-110 was significantly higher than that of MPA, though JP-3-110 was still poorly water-soluble. The ester bond connecting KZ41 and MPA is stable for a limited duration (<4 weeks). Pharmacological studies demonstrated that JP-3-110 induced significantly less activated caspase 3 and apoptotic cell death of human islets than MPA, while maintaining an equally potent immunosuppressive effect. A similar immunosuppressive effect of JP-3-110 and MPA in humanized NOD.Cg-PrkdcscidIl2rgtm1Wjl/SzJ (NOD scid gamma, NSG) mice with adoptively transferred human immunity was observed. Taken together, our results demonstrated that JP-3-110 can be a safer immunosuppressive agent for human islet transplantation.

AB - Mycophenolic acid (MPA) is a commonly used immunosuppressive drug for human islet transplantation. However, it is toxic to transplanted islets, causing primary nonfunction. We recently synthesized a quinic acid derivative, 1,3,4,5-tetrahydroxy-N-propylcyclohexanecarboxamide (KZ41), which has anti-inflammatory and anti-apoptotic effects. We hypothesized that the conjugate (E)-2,3,5-trihydroxy-5-(propylcarbamoyl) cyclohexyl 6-(4-ethoxy-6-methoxy-7- methyl-3-oxo-1,3-dihydroisobenzofuran-5-yl)-4-methylhex-4-enoate (JP-3-110), which is composed of KZ41 and MPA through esterification, can suppress the immune rejection while inducing less toxicity. Early characterization showed that the solubility of JP-3-110 was significantly higher than that of MPA, though JP-3-110 was still poorly water-soluble. The ester bond connecting KZ41 and MPA is stable for a limited duration (<4 weeks). Pharmacological studies demonstrated that JP-3-110 induced significantly less activated caspase 3 and apoptotic cell death of human islets than MPA, while maintaining an equally potent immunosuppressive effect. A similar immunosuppressive effect of JP-3-110 and MPA in humanized NOD.Cg-PrkdcscidIl2rgtm1Wjl/SzJ (NOD scid gamma, NSG) mice with adoptively transferred human immunity was observed. Taken together, our results demonstrated that JP-3-110 can be a safer immunosuppressive agent for human islet transplantation.

UR - http://www.scopus.com/inward/record.url?scp=84890820212&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84890820212&partnerID=8YFLogxK

U2 - 10.1021/bc400369t

DO - 10.1021/bc400369t

M3 - Article

C2 - 24256337

AN - SCOPUS:84890820212

VL - 24

SP - 2036

EP - 2044

JO - Bioconjugate Chemistry

JF - Bioconjugate Chemistry

SN - 1043-1802

IS - 12

ER -